$235 Million is the total value of TCG Crossover Management, LLC's 22 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KDNY | Sell | Chinook Therapeutics, Inc. | $13,930,000 | -3.5% | 796,460 | -9.7% | 5.92% | +2.1% |
| Sell | Tango Therapeutics, Inc. | $5,310,000 | -44.2% | 1,172,250 | -6.6% | 2.26% | -40.9% | |
| ALPN | Sell | Alpine Immune Sciences, Inc. | $4,921,000 | -47.0% | 578,260 | -44.1% | 2.09% | -43.9% |
| Sell | Pardes Biosciences, Inc. | $181,000 | -89.1% | 59,039 | -74.2% | 0.08% | -88.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.